|

Oxford scientists believe they could have breakthrough on Covid-19 vaccine – Telegraph

Oxford scientists believe they could have a breakthrough on Covid-19 vaccine, which is reported in the Telegraph today. 

Key notes

  • The clinical trials have so far been successful, the Telegraph understands.
  • Researchers have shown that antibodies produced against sections of a genetic material called spike protein, usually found on the surface of the coronavirus, after infection are able to kill the virus when tested in the laboratory.  
  • They want the human body to recognise and develop antibodies to the protein that would stop the virus from entering human cells.
  • Trials suggest that not only is this happening but also that the body is developing a crucial T-cell response as well, which is deemed crucial in the defence against coronavirus.

When will it be available?

The article states that AstraZeneca is on track to begin rolling out up to two billion doses of a coronavirus vaccine in September if ongoing trials continue to prove successful.

What is the next step?

As the level of coronavirus in the UK subsided, scientists began trialling the drug in hospitals, where it was likely to be more prevalent.

They have also enrolled 5,000 volunteers in Brazil and others in South Africa.

Developers are expected to report their Phase I study results - which would show whether it is safe and whether or not it induces an immune response - within the next fortnight.

Market implications

"Bring it on!", say the bulls. 

Author

Ross J Burland

Ross J Burland, born in England, UK, is a sportsman at heart. He played Rugby and Judo for his county, Kent and the South East of England Rugby team.

More from Ross J Burland
Share:

Markets move fast. We move first.

Orange Juice Newsletter brings you expert driven insights - not headlines. Every day on your inbox.

By subscribing you agree to our Terms and conditions.

Editor's Picks

EUR/USD eases from around 1.1800 after US GDP figures

The US Dollar is finding some near-term demand after the release of the US Q3 GDP. According to the report, the economy expanded at an annualized rate of 4.3% in the three months to September, well above the 3.3% forecast by market analysts.

GBP/USD retreats below 1.3500 on modest USD recovery

GBP/USD retreats from session highs and trades slightly below 1.3500 in the second half of the day on Tuesday. The US Dollar stages a rebound following the better-than-expected Q3 growth data, limiting the pair's upside ahead of the Christmas break.

Gold trims intraday gains, overs around 4,450

Gold prices soared to $4,497 early on Monday, as persistent US Dollar weakness and thinned holiday trading exacerbated the bullish run. The bright metal eases following the release of an upbeat US Q3 GDP reading, as USD finds near-term demand in the American session.

Crypto Today: Bitcoin, Ethereum, XRP decline as risk-off sentiment escalates

Bitcoin remains under pressure, trading above the $87,000 support at the time of writing on Tuesday. Selling pressure has continued to weigh on the broader cryptocurrency market since Monday, triggering declines across altcoins, including Ethereum and Ripple.

Ten questions that matter going into 2026

2026 may be less about a neat “base case” and more about a regime shift—the market can reprice what matters most (growth, inflation, fiscal, geopolitics, concentration). The biggest trap is false comfort: the same trades can look defensive… right up until they become crowded.

Dogecoin ticks lower as low Open Interest, funding rate weigh on buyers

Dogecoin extends its decline as risk-off sentiment dominates across the crypto market. DOGE’s derivatives market remains weak amid suppressed futures Open Interest and perpetual funding rate.